Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings Ocular Therapeutix shares are trading lower by 13.3% Monday afternoon. The company reported worse-than-expected Q1 financial results.
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli's potential in wet AMD and forecasting $1.5 billion peak sales.
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026.
3 Biotech Stocks to Sell in August Before They Crash & Burn Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains.
